NCT06116786

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 126 (estimated)
• Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Conditions

• Carcinoma, Non-small-Cell Lung

Interventions

Type	Name	Description
DRUG	JNJ-86974680	JNJ-86974680 will be administered.
DRUG	Cetrelimab	Cetrelimab will be administered.
RADIATION	Radiation Therapy	Radiation therapy will be administered.

Timeline

• Start date: 2023-11-27
• Primary completion: 2027-04-14
• Completion: 2029-06-07
• First posted: 2023-11-03
• Last updated: 2026-04-13

Locations

15 sites across 4 countries: United States, Germany, South Korea, Spain

Regulatory

• FDA-regulated drug study